[SIRS and the coagulation of normality]

Area of Science:

• Pathophysiology
• Hematology
• Immunology

Background:

• Systemic inflammatory response syndrome (SIRS) is a critical condition linked to infection and injury, often progressing to multiple organ dysfunction syndrome and disseminated intravascular coagulation (DIC).
• Cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta, play a key role in SIRS pathogenesis.
• These cytokines promote coagulation by activating monocytes and endothelial cells to express tissue factor, initiating microthrombus formation.

Purpose of the Study:

• To elucidate the mechanisms by which cytokines contribute to DIC in SIRS.
• To evaluate the potential therapeutic efficacy of anticoagulants in managing SIRS-associated DIC.

Main Methods:

• Review of the molecular mechanisms underlying cytokine-mediated coagulation activation in SIRS.
• Analysis of the role of endothelial cell activation, tissue factor expression, and anticoagulant pathways.

Main Results:

• Cytokines (TNF-alpha, IL-1 beta) induce tissue factor expression, leading to microthrombus formation and DIC.
• Cytokines also impair anticoagulant mechanisms by reducing thrombomodulin and glycosaminoglycan expression on endothelial cells.
• Endothelial cell injury and microthrombi contribute to microcirculatory disturbances and ischemic organ dysfunction.

Conclusions:

• Cytokine-driven pathways are central to the development of DIC in SIRS.
• Physiological anticoagulants (antithrombin, activated protein C) show potential for treating SIRS-associated DIC by inhibiting leukocyte activation.
• Heparin may not be effective in this context due to its inability to prevent endothelial cell injury.